Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Quantum rods and dots image cancer cells

Brightly fluorescent quantum dots and quantum rods are quickly becoming important tools for identifying specific molecules and cells in living systems. Two new reports demonstrate some of the ways in which cancer researchers are using these nanoscale imaging agents.

26 Feb 2007

Scientists discover master switches for adult blood stem cells

Johns Hopkins Kimmel Cancer Center scientists have found a set of "master switches" that keep adult blood-forming stem cells in their primitive state.

8 Feb 2007

Bright quantum dots help basic cancer biology studies

Though there is little doubt that nanoscale devices are going to play a critical role in improving cancer detection and treatment over the next five to ten years, nanoparticles are already having a major impact on the way that cancer biologists study the processes that go awry within malignant and metastatic cells.

5 Feb 2007

Cruelty-free ELISA for human insulin

In the January issue of Clinical Biochemistry, scientists and physicians with the Physicians Committee for Responsible Medicine (PCRM) outline the method used to develop a cruelty-free ELISA for human insulin that uses monoclonal antibodies produced by cells cultured in an animal-serum-free medium.

30 Jan 2007

Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients

The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.

18 Jan 2007

Cancer Research Technology to present discovery updates at BioEurope 2006

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announce that Phil L'Huillier, the Director of Business Management, will present at the BioEurope 2006 Annual International Partnering Conference.

6 Nov 2006

Vaccine that protects mice against 1918 influenza virus developed

Federal scientists have developed a vaccine that protects mice against the killer 1918 influenza virus. They also have created a technique for identifying antibodies that neutralize this virus, a tool that could help contain future pandemic flu strains.

17 Oct 2006

Renal transplantation in children with posterior uUrethral valves

The first description of posterior urethral valves (PUV) was made more than 80 years ago by Hugh Hampton Young and represents a spectrum of severity, ranging from disease incompatible with postnatal life to minimal symptoms that may not manifest until later in life.

17 Aug 2006

Drug trial fiasco induced immune system overload in patients

The doctors who treated six British men in a trial of a drug in March which went horribly wrong, say they believe the men suffered an immune system overreaction known as a cytokine storm.

15 Aug 2006

Researchers find precise location where an antibody binds to the West Nile virus

Researchers have learned the precise location where an antibody binds to the West Nile virus, and they have suggested a mechanism for how this antibody neutralizes the virus to prevent infection.

14 Aug 2006

HHS to stockpile Anthrax immune globulin

The Department of Health and Human Services (HHS) has announced it will purchase 10,000 therapeutic courses of treatment of Anthrax Immune Globulin (AIG) from Cangene Corporation of Winnipeg, Manitoba, Canada for a total of $143,833,719.

30 Jul 2006

Buckyballs deliver multiple drugs simultaneously to tumors

Combining a monoclonal antibody known to target melanoma tumors with multiple C60 buckyballs, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have developed a new way to deliver multiple drugs simultaneously to tumors.

3 Jul 2006

First-in-class biologics poised to drive malignant melanoma drug market

Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.

27 Jun 2006

Trastuzumab results promising for HER-2 positive breast cancer patients

Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.

7 Jun 2006

FDA approves resumed marketing of Tysabri

The Food and Drug Administration (FDA) today approved an application for resumed marketing of Tysabri (natalizumab) subject to a special restricted distribution program.

5 Jun 2006

Drug combo might beat type 1 diabetes

Scientists in California have developed a cocktail of drugs which can reverse diabetes and say the discovery is an important step towards a potential cure.

23 Apr 2006

Lack of response to herceptin may be reversed with PI3K inhibiting agents

Breast cancer patients with HER2-positive tumors who don't respond to Herceptin (trastuzumab) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, say researchers at the University of Texas M. D. Anderson Cancer Center.

11 Apr 2006

Panitumumab shows promise for patients with colorectal cancer

Results from a Phase III study of a new drug show promise for patients with colorectal cancer that has spread to other parts of the body, according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.

4 Apr 2006

Natural killer cells and antibody-based immune function

A new drug may boost the effectiveness of a widely used treatment for patients with non-Hodgkin lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.

4 Apr 2006

African American women urged to confront colorectal cancer

Despite having the greatest risk of developing and dying from colorectal cancer (CRC) of any gender, race or ethnicity, an astounding 96 percent of African American women do not consider themselves to be at high risk for the disease, according to a new Harris poll.

17 Mar 2006